Allakos Receives $32,000,000 Series A Funding Round

  • Feed Type
  • Date
    12/18/2012
  • Company Name
    Allakos
  • Mailing Address
    Undisclosed San Francisco, CA 94105
  • Company Description
    Allakos Inc. is a privately held, product-focused biotechnology company developing first-in-class antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 (Th2) immune response plays a key role in pathology, including allergic disease, inflammation and diseases characterized by excess production of inflammatory cells. Allakos has generated a preclinical pipeline of novel antibodies targeting cell types implicated in allergic and inflammatory responses, which it intends to advance to clinical proof-of-concept.
  • Website
    http://www.allakos.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $32,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
    Novo A/S
  • Venture Investor
    Alta Partners
  • Venture Investor
    RiverVest Venture Partners
  • Venture Investor
    Roche Venture Fund

By posting a comment, you agree to our terms and conditions.